Paper15534239
Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
Krupp LB and 5 others. Neurology, 2004. Cited by 187 papers, by iCite.
Cite this record
ConductScience Library. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Papers, record 15534239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15534239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cholinesterase Inhibitors | Major topic |
| Indans | Major topic |
| Memory | Major topic |
| Multiple Sclerosis | Major topic |
| Nootropic Agents | Major topic |
| Piperidines | Major topic |
| Adolescent | |
| Adult | |
| Donepezil | |
| Double-Blind Method | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HD38107-01 | NICHD NIH HHS | United States | PubMed | PubMed | |
| M01-RR10710-02 | NCRR NIH HHS | United States | M01RR107100 | PubMed | NIH RePORTER |
| M01RR010710 | NIH | NIH RePORTER | |||
| R01HD038107 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00315367 | A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties | Background |
Source ClinicalTrials.gov
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 15534232 | Treating cognitive deficits in multiple sclerosis: are we there yet? | https://conductscience.org/library/papers/15534232 | PubMed |
| Comment in | 15911833 | Donepezil improved memory in multiple sclerosis in a randomized clinical trial. | https://conductscience.org/library/papers/15911833 | PubMed |
Cited by64
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41127289 | Pharmacological treatment options for cognitive dysfunction induced by multiple sclerosis: a network meta-analysis. | Front Neurol | 2025 | https://conductscience.org/library/papers/41127289 | PubMed |
| 38709986 | Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38709986 | PubMed |
| 37508875 | Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review. | Bioengineering (Basel) | 2023 | https://conductscience.org/library/papers/37508875 | PubMed |
| 37445309 | Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges. | J Clin Med | 2023 | https://conductscience.org/library/papers/37445309 | PubMed |
| 35822102 | Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis. | Brain Commun | 2022 | https://conductscience.org/library/papers/35822102 | PubMed |
| 33588903 | Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/33588903 | PubMed |
| 33299606 | Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients. | Neurol Res Int | 2020 | https://conductscience.org/library/papers/33299606 | PubMed |
| 32742613 | Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial. | Int J Prev Med | 2020 | https://conductscience.org/library/papers/32742613 | PubMed |
| 32361940 | Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review. | CNS Drugs | 2020 | https://conductscience.org/library/papers/32361940 | PubMed |
| 31659498 | Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. | EJNMMI Radiopharm Chem | 2019 | https://conductscience.org/library/papers/31659498 | PubMed |
| 31467038 | Glutamine antagonism attenuates physical and cognitive deficits in a model of MS. | Neurol Neuroimmunol Neuroinflamm | 2019 | https://conductscience.org/library/papers/31467038 | PubMed |
| 30893874 | Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. | Biomedicines | 2019 | https://conductscience.org/library/papers/30893874 | PubMed |
| 30303036 | Recommendations for cognitive screening and management in multiple sclerosis care. | Mult Scler | 2018 | https://conductscience.org/library/papers/30303036 | PubMed |
| 29770225 | Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105. | Neurooncol Pract | 2018 | https://conductscience.org/library/papers/29770225 | PubMed |
| 29356970 | Cognitive phenotypes in multiple sclerosis. | J Neurol | 2018 | https://conductscience.org/library/papers/29356970 | PubMed |
| 29119933 | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis. | Curr Neuropharmacol | 2018 | https://conductscience.org/library/papers/29119933 | PubMed |
| 29079868 | [New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation]. | Nervenarzt | 2018 | https://conductscience.org/library/papers/29079868 | PubMed |
| 28374837 | Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients. | Sci Rep | 2017 | https://conductscience.org/library/papers/28374837 | PubMed |
| 28360700 | The Effects of Cognitive Rehabilitation on Relapsing Remitting Multiple Sclerosis Patients. | Noro Psikiyatr Ars | 2015 | https://conductscience.org/library/papers/28360700 | PubMed |
| 28360664 | A Case of Cortical Multiple Sclerosis. | Noro Psikiyatr Ars | 2014 | https://conductscience.org/library/papers/28360664 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15534239
GET https://conductscience.org/api/papers/v1/15534239/cited_by?page=2